Misbadi (Dabigatran Etexilate)

Dabigatran etexilate, the active ingredient in Misbadi, is a direct thrombin inhibitor presented as an oral tablet for oral use. It is used to reduce the risk of stroke and systemic embolism in patients with non‑valvular atrial fibrillation and to treat and prevent deep vein thrombosis and pulmonary embolism.

GNH USA supplies Misbadi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Misbadi is a direct thrombin inhibitor indicated for several thrombo‑embolic conditions.

- Non‑valvular atrial fibrillation: reduces the risk of stroke and systemic embolism. - Deep vein thrombosis (DVT): treats acute DVT and helps prevent recurrence. - Pulmonary embolism (PE): treats acute PE and helps prevent recurrence.

Common side effects are generally mild and related to the gastrointestinal tract.

Common Side Effects: - Dyspepsia: upset stomach or indigestion. - Gastrointestinal bleeding: minor bleeding from the gut. - Nausea: feeling of sickness. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Major bleeding: potentially life‑threatening hemorrhage. - Hemorrhagic stroke: bleeding within the brain. - Myocardial infarction: rare heart attack events. - Hepatic injury: liver function abnormalities. - Allergic reactions: including anaphylaxis. - Thrombocytopenia: low platelet count.

Before prescribing Misbadi, clinicians should evaluate several safety factors.

- Renal function assessment: evaluate creatinine clearance prior to initiation. - Bleeding risk assessment: avoid in patients with active major bleeding. - Concomitant antiplatelet therapy: use caution when combined with aspirin or clopidogrel. - Surgery or invasive procedures: discontinue according to recommended timing before procedures. - Elderly patients: monitor closely for bleeding complications. - Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture.

Misbadi may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong P‑gp inhibitors (e.g., ketoconazole, itraconazole): may increase dabigatran exposure. - Combined use with other anticoagulants (e.g., warfarin, heparin): heightened bleeding risk. - NSAIDs and antiplatelet agents: increased risk of gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - P‑gp inducers (e.g., rifampin, carbamazepine): may reduce dabigatran efficacy. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously. - Certain antiviral agents (e.g., ritonavir): may alter plasma levels of dabigatran.